Innoviva (INVA) Competitors $18.77 -0.29 (-1.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$17.86 -0.91 (-4.84%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INVA vs. ALKS, LGND, BCRX, FOLD, CLDX, DVAX, MNKD, OPK, NVAX, and GERNShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), and Geron (GERN). These companies are all part of the "biotechnology" industry. Innoviva vs. Its Competitors Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Dynavax Technologies MannKind OPKO Health Novavax Geron Alkermes (NASDAQ:ALKS) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Which has better valuation & earnings, ALKS or INVA? Alkermes has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.21$367.07M$2.0914.49Innoviva$358.71M3.29$23.39M-$1.01-18.58 Is ALKS or INVA more profitable? Alkermes has a net margin of 23.30% compared to Innoviva's net margin of -16.15%. Alkermes' return on equity of 27.52% beat Innoviva's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.30% 27.52% 17.98% Innoviva -16.15%15.77%8.41% Does the media prefer ALKS or INVA? In the previous week, Alkermes had 2 more articles in the media than Innoviva. MarketBeat recorded 7 mentions for Alkermes and 5 mentions for Innoviva. Alkermes' average media sentiment score of 1.39 beat Innoviva's score of 0.74 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ALKS or INVA? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.4% of Alkermes shares are held by company insiders. Comparatively, 2.3% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, ALKS or INVA? Alkermes has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Do analysts recommend ALKS or INVA? Alkermes currently has a consensus target price of $40.00, suggesting a potential upside of 32.10%. Innoviva has a consensus target price of $40.50, suggesting a potential upside of 115.77%. Given Innoviva's stronger consensus rating and higher possible upside, analysts plainly believe Innoviva is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Innoviva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAlkermes beats Innoviva on 13 of the 17 factors compared between the two stocks. Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18B$254.33B$5.56B$9.11BDividend YieldN/A2.83%5.06%4.01%P/E Ratio-18.5827.9128.2620.26Price / Sales3.295.00437.10166.10Price / Cash5.4813.9337.1257.67Price / Book1.7017.848.045.49Net Income$23.39M$8.49B$3.19B$250.45M7 Day Performance-2.24%0.73%3.62%4.79%1 Month Performance-13.46%-2.20%5.98%9.59%1 Year Performance12.19%-5.29%29.39%16.41% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva4.1109 of 5 stars$18.77-1.5%$40.50+115.8%+12.2%$1.18B$358.71M-18.58100News CoverageAnalyst ForecastAnalyst RevisionALKSAlkermes4.7999 of 5 stars$28.61-0.7%$40.00+39.8%+28.5%$4.75B$1.56B13.691,800Positive NewsLGNDLigand Pharmaceuticals4.0777 of 5 stars$113.68-0.4%$146.14+28.6%+22.4%$2.20B$167.13M-15.9780News CoverageInsider TradeBCRXBioCryst Pharmaceuticals4.2116 of 5 stars$8.96-4.3%$16.89+88.5%+22.5%$1.96B$450.71M-34.46530FOLDAmicus Therapeutics4.1348 of 5 stars$5.73-3.4%$16.22+183.1%-41.5%$1.83B$528.29M-63.66480News CoverageAnalyst RevisionCLDXCelldex Therapeutics2.494 of 5 stars$20.35+0.3%$50.11+146.2%-42.4%$1.35B$7.02M-7.54150Positive NewsDVAXDynavax Technologies4.3726 of 5 stars$9.92+0.1%$24.00+141.9%-1.6%$1.19B$277.25M-19.08350News CoverageMNKDMannKind2.439 of 5 stars$3.74-0.5%$10.33+176.3%-33.9%$1.14B$285.50M37.40400OPKOPKO Health4.1463 of 5 stars$1.32flat$2.75+108.3%-2.2%$1.05B$713.10M-18.852,997News CoveragePositive NewsAnalyst UpgradeNVAXNovavax4.3509 of 5 stars$6.30-1.1%$17.00+169.8%-47.8%$1.03B$682.16M2.381,990GERNGeron3.3575 of 5 stars$1.41-5.4%$5.06+259.0%-72.0%$949.01M$76.99M-6.7170News CoverageAnalyst ForecastGap Down Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives MannKind Alternatives OPKO Health Alternatives Novavax Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVA) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
